8.99
-0.07 (-0.77%)
| Previous Close | 9.06 |
| Open | 9.07 |
| Volume | 3,014,346 |
| Avg. Volume (3M) | 7,021,664 |
| Market Cap | 1,041,311,040 |
| Price / Sales | 16.79 |
| Price / Book | 1.43 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -726.57% |
| Diluted EPS (TTM) | -5.23 |
| Quarterly Revenue Growth (YOY) | -42.50% |
| Total Debt/Equity (MRQ) | 15.29% |
| Current Ratio (MRQ) | 4.90 |
| Operating Cash Flow (TTM) | -377.15 M |
| Levered Free Cash Flow (TTM) | -150.18 M |
| Return on Assets (TTM) | -30.12% |
| Return on Equity (TTM) | -57.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Intellia Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.98% |
| % Held by Institutions | 97.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 30 Sep 2025 | 3,702,995 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (B of A Securities, 233.70%) | Buy |
| Median | 14.00 (55.73%) | |
| Low | 5.00 (JP Morgan, -44.38%) | Sell |
| Average | 15.73 (74.97%) | |
| Total | 7 Buy, 5 Hold, 1 Sell | |
| Avg. Price @ Call | 10.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 11 Nov 2025 | 8.00 (-11.01%) | Hold | 10.18 |
| HC Wainwright & Co. | 10 Nov 2025 | 15.00 (66.85%) | Buy | 9.73 |
| 30 Oct 2025 | 18.00 (100.22%) | Buy | 12.27 | |
| Truist Securities | 10 Nov 2025 | 14.00 (55.73%) | Buy | 9.73 |
| Barclays | 07 Nov 2025 | 14.00 (55.73%) | Buy | 9.52 |
| 28 Oct 2025 | 24.00 (166.96%) | Buy | 13.96 | |
| Chardan Capital | 07 Nov 2025 | 26.00 (189.21%) | Buy | 9.52 |
| 27 Oct 2025 | 48.00 (433.93%) | Buy | 14.79 | |
| Citizens | 07 Nov 2025 | 21.00 (133.59%) | Buy | 9.52 |
| JP Morgan | 07 Nov 2025 | 5.00 (-44.38%) | Sell | 9.52 |
| RBC Capital | 07 Nov 2025 | 9.00 (0.11%) | Hold | 9.52 |
| 28 Oct 2025 | 14.00 (55.73%) | Hold | 13.96 | |
| Wedbush | 07 Nov 2025 | 7.00 (-22.14%) | Hold | 9.52 |
| Wells Fargo | 07 Nov 2025 | 12.00 (33.48%) | Hold | 9.52 |
| 28 Oct 2025 | 17.00 (89.10%) | Hold | 13.96 | |
| Bernstein | 28 Oct 2025 | 14.50 (61.29%) | Hold | 13.96 |
| JMP Securities | 28 Oct 2025 | 29.00 (222.58%) | Buy | 13.96 |
| B of A Securities | 27 Oct 2025 | 30.00 (233.70%) | Buy | 14.79 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BASTA JAMES | - | 9.37 | -10,397 | -97,420 |
| CLARK ELIANA | - | 9.37 | -9,515 | -89,156 |
| COHEN FRED E | 9.37 | - | 150,000 | 1,405,500 |
| DUBE MICHAEL P | - | 9.37 | -2,989 | -28,007 |
| DULAC EDWARD J III | - | 9.37 | -6,379 | -59,771 |
| LEBWOHL DAVID | - | 9.37 | -11,903 | -111,531 |
| LEONARD JOHN M | - | 9.37 | -34,146 | -319,948 |
| SCHULTES BIRGIT C | - | 9.37 | -8,508 | -79,720 |
| Aggregate Net Quantity | 66,163 | |||
| Aggregate Net Value ($) | 619,947 | |||
| Aggregate Avg. Buy ($) | 9.37 | |||
| Aggregate Avg. Sell ($) | 9.37 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DUBE MICHAEL P | Officer | 05 Jan 2026 | Sell (-) | 2,989 | 9.37 | 28,007 |
| DULAC EDWARD J III | Officer | 05 Jan 2026 | Sell (-) | 6,379 | 9.37 | 59,771 |
| CLARK ELIANA | Officer | 05 Jan 2026 | Sell (-) | 9,515 | 9.37 | 89,156 |
| LEBWOHL DAVID | Officer | 05 Jan 2026 | Sell (-) | 11,903 | 9.37 | 111,531 |
| COHEN FRED E | Director | 05 Jan 2026 | Buy (+) | 150,000 | 9.37 | 1,405,500 |
| BASTA JAMES | Officer | 05 Jan 2026 | Sell (-) | 10,397 | 9.37 | 97,420 |
| SCHULTES BIRGIT C | Officer | 05 Jan 2026 | Sell (-) | 8,508 | 9.37 | 79,720 |
| LEONARD JOHN M | Officer | 05 Jan 2026 | Sell (-) | 34,146 | 9.37 | 319,948 |
| Date | Type | Details |
|---|---|---|
| 05 Dec 2025 | Announcement | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 10 Nov 2025 | Announcement | Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy |
| 08 Nov 2025 | Announcement | Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema |
| 06 Nov 2025 | Announcement | Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates |
| 27 Oct 2025 | Announcement | Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |